Menu

Oncologists’ Usage of Biomarker Testing is Growing, but Opportunities for Increased Use Remain

Biomarkers are molecules found in bodily fluids or tissues (including the tumor tissue). They provide valuable information about the cancer cells and non-cancer cells, when analyzing which biomarkers are produced in response to the cancer. By developing a biomarker profile of a patient’s cancer, doctors can recommend the best suited treatment plan. This insight allows patients, who are more likely to respond to a targeted drug, avoid treatments that would be less beneficial. Biomarker testing is now widely used among Canadian oncologists, but barriers to expanding their use remain.

Read More

We asked 32 Canadian Oncologists about their current use and perceptions of biomarker testing, and the role it plays in their management of cancer. All oncologists interviewed claimed to have requested biomarker testing at least once in the past 6 months. When combining all cancer types together, biomarker testing is requested for 50% of patients.

Biomarker testing is used in these cancer types: lung, breast, skin, leukemia and brain. The survey results confirm the opportunity to further invest in research to support testing in the following cancer types: neuro-endocrine, pancreas, urothelial, kidney and liver.

Despite the growing use of biomarker testing, significant barrier remain. 75% of physicians say delays in receiving test results negatively impact their use. 59% of physicians say cost prevents them from using as often as they’d like. 100% of oncologists strongly believe that targeted therapy through the use of biomarket testing is very important for the future of cancer treatment.

 

Past Quick Polls

Pandemic’s Impact on HCPs Practices and Vaccination Campaign Perceptions

The COVID-19 vaccination campaign is underway in Canada. However, the pandemic has significantly altered HCPs’ practices to date. These changes have impacted workloads, patient assessments, and interactions with pharma. A year into the pandemic, a national COVID-19 vaccination campaign is underway. This begs the question, how are Canadian HCPs doing today? What do they foresee moving forward?

Our latest short survey presents the current state of HCPs’ practices in Canada and their assessment of the government’s management of COVID-19 since the start of the pandemic. It also delves into the changes in the modes of interactions with both patients and the pharmaceutical industry. Continue reading and check out our infographic to learn more about how HCPs have been impacted and what changes are here to stay.  

read more

Remote Detailing for Pharma – Physicians’ perspectives

Our 5-minute online survey conducted in the fall of 2020 sought to gain clarity around remote detailing. This study was conducted with 339 Canadian physicians who are members of the MD Analytics healthcare panel and the results provide actionable recommendations on how to form a more ‘ideal’ pharma remote detail.

read more

Does Online Advertising Click for Physicians?

Strong online advertising and messaging are key to maximizing impact of any marketing campaign. With recent restrictions on in-person interactions, online advertising and messaging play an even greater role in reaching physicians. Our findings from a survey of n=227 Canadian physicians show that 82% of Canadian physicians have increased their use of online platforms as a result of COVID-19, 48% significantly so.

read more

We are here to answer your questions.

Share This